Sonnet BioTherapeutics Holdings, Inc. (SONN): Price and Financial Metrics
SONN Price/Volume Stats
| Current price | $1.77 | 52-week high | $26.40 |
| Prev. close | $1.70 | 52-week low | $1.08 |
| Day low | $1.70 | Volume | 17,900 |
| Day high | $1.78 | Avg. volume | 92,572 |
| 50-day MA | $1.86 | Dividend yield | N/A |
| 200-day MA | $3.19 | Market Cap | 5.43M |
SONN Stock Price Chart Interactive Chart >
Sonnet BioTherapeutics Holdings, Inc. (SONN) Company Bio
Sonnet BioTherapeutics Holdings, Inc. operates as a clinical stage biotechnology company. The Company develops fully human albumin binding technology that helps the development of innovative targeted biologic drugs with enhanced single-or bi-specific mechanisms. Sonnet BioTherapeutics Holdings serves customers in the United States.
Latest SONN News From Around the Web
Below are the latest news stories about SONNET BIOTHERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate SONN as an investment opportunity.
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor ImmunotherapyPRINCETON, NJ / ACCESSWIRE / December 21, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of extensive preclinical data on ... |
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial UpdatePRINCETON, NJ / ACCESSWIRE / December 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs focused on oncology, announced today its financial ... |
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business OverviewFollowing the recent completion of a $4.55 million financing, Sonnet projects cash runway into the calendar year third quarter of 2024The company is focused on its business development initiatives and anticipates being able to provide an update in ... |
Why Is Sonnet BioTherapeutics (SONN) Stock Down 33% Today?Sonnet BioTherapeutics stock is dropping on Wednesday after the company revealed the pricing of a public offering for SONN shares. |
EVGO Stock Slips as TD Cowen Downgrades EVgoEVgo stock is taking a beating on Wednesday as investors in the EV charging company deal with a downgrade and price cut. |
SONN Price Returns
| 1-mo | -14.49% |
| 3-mo | 33.08% |
| 6-mo | -25.32% |
| 1-year | -73.60% |
| 3-year | -99.71% |
| 5-year | -99.99% |
| YTD | 1.72% |
| 2023 | -93.12% |
| 2022 | -80.12% |
| 2021 | -81.48% |
| 2020 | -85.46% |
| 2019 | -54.26% |
Loading social stream, please wait...